Clinical Utility of Neuromodulation on Tinnitus

Clinical Utility of Neuromodulation on Tinnitus: A Systematic Review

The aim of the present narrative review is to one of the first to critically evaluate the clinical effectiveness of neuromodulation as a therapeutic option for patients with tinnitus. Our method involves conducting a systemic review and the findings reported following PRISMA statement. Pubmed, Cochrane database and Google Scholar databases literature search was conducted for articles reporting the use of neuromodulatory interventions on tinnitus patients. Each article was evaluated using the Cochrane risk of bias tool.

Study Overview

• Status: Completed
• Conditions: Tinnitus

• Study Type: Observational
• Enrollment (Actual): 26

Contacts and Locations

Study Locations

• Taiwan
  • Hsinchu, Taiwan
    • Hearing and Language Healthcare Center, China Medical University Hsinchu Hospital, Taiwan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Tinnitus patients

Description

Inclusion Criteria:

• Tinnitus patients
• At least one of the neurofeedback methods
• Single and multi-center
• Randomized control trials and observational studies

Exclusion Criteria:

• Non-peer-reviewed papers, letters, editorials
• Not English language

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Tinnitus severity scores	9 months

Collaborators and Investigators

• Sponsor: Hearing and Language Healthcare Center, China Medical University Hsinchu Hospital, Taiwan

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): June 30, 2022
• Study Completion (Actual): September 30, 2022

Study Registration Dates

• First Submitted: December 30, 2022
• First Submitted That Met QC Criteria: December 30, 2022
• First Posted (Estimate): January 6, 2023

Study Record Updates

• Last Update Posted (Estimate): January 6, 2023
• Last Update Submitted That Met QC Criteria: December 30, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Otorhinolaryngologic Diseases; Ear Diseases; Sensation Disorders; Hearing Disorders; Tinnitus
• Other Study ID Numbers: IJS-D-22-01675

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No